-
Mashup Score: 3Study reveals inequities in access to CAR T cell therapy - 1 day(s) ago
Patients being treated for B-cell non-Hodgkin’s Lymphoma (NHL) who are part of minority populations may not have equal access to cutting-edge CAR T cell therapies, according to a new analysis led by researchers …
Source: medicalxpress.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1FDA requires boxed safety warning for all CAR T-cell therapies - 2 month(s) ago
The FDA has requested manufacturers of commercially available chimeric antigen receptor T-cell therapies now include a boxed safety warning regarding the risk for secondary T-cell malignancies on prescribing labels.The agency delivered the decision via letters to the five companies that manufacture six FDA-approved CAR T-cell therapies. Among them are the CD19-directed agents axicabtagene
Source: www.healio.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting - 8 month(s) ago
Nature Communications – Targeting solid tumours by chimeric antigen receptor (CAR) T cells require strategies that improve trafficking and effector function of these cells in the immunologically…
Source: www.nature.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 6MSK Research Highlights July 17, 2023 - 8 month(s) ago
New MSK research identified a way to reduce toxicity in CAR T cell therapy; discovered a division of labor in DNA repair that suggests a possible therapeutic strategy for certain cancers; developed a new method to enable imaging of two PET tracers simultaneously; found biomarkers that could help predict outcomes in HER2-positive metastatic esophagogastric cancer; and made progress toward…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Carlos Fernández de Larrea and Damian Green on BCMA CAR T cells in multiple myeloma - In conversation with... - 9 month(s) ago
Carlos Fernández de Larrea (Hospital ClÃnic de Barcelona, Barcelona, Spain) and Damian Green (Fred Hutch Cancer Center, Seattle, WA, USA) discuss their studies on BCMA CAR T cells in patients with relapsed or refractory multiple myeloma.Read the f…
Source: BuzzsproutCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0FDA places clinical hold on trial of CAR-T for advanced myeloma after patient death - 9 month(s) ago
The FDA placed a clinical hold on a clinical program designed to investigate a chimeric antigen receptor T-cell therapy for treatment of relapsed or refractory multiple myeloma following a patient death.The hold applies to IMMagine-1, a multicenter phase 2 trial evaluating the investigational therapy CART-ddBCMA (Arcellx Inc.).
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0FDA places clinical hold on trial of CAR-T for advanced myeloma after patient death - 9 month(s) ago
The FDA placed a clinical hold on a clinical program designed to investigate a chimeric antigen receptor T-cell therapy for treatment of relapsed or refractory multiple myeloma following a patient death.The hold applies to IMMagine-1, a multicenter phase 2 trial evaluating the investigational therapy CART-ddBCMA (Arcellx Inc.).
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1CAR-T ‘definitively’ superior as second-line therapy for large B-cell lymphoma - 10 month(s) ago
CHICAGO — Second-line therapy with axicabtagene ciloleucel conferred a significant increase in OS compared with the current standard of care among adults with relapsed or refractory large B-cell lymphoma, results of the randomized phase 3 ZUMA-7 study showed.Treatment with the chimeric antigen receptor T-cell therapy reduced the risk for death by 27.4% compared with standard care, updated
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Episode 2: Monitoring and Management of CAR T-Cell Therapy Complications - 10 month(s) ago
Join Drs Amelia Langston and Jean Koff as they discuss the monitoring and management of complications before, during, and after CAR T-cell therapy.
Source: MedscapeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Episode 2: Monitoring and Management of CAR T-Cell Therapy Complications - 10 month(s) ago
Join Drs Amelia Langston and Jean Koff as they discuss the monitoring and management of complications before, during, and after CAR T-cell therapy.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet
Study reveals inequities in access to #CARTCellTherapy @pennmedicine @NEJMEvidence https://t.co/gIXzNyrVtj